Amoxicillin
Product Images NDC 61919-366

8 FDA label images from Direct Rx · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Amoxicillin (NDC 61919-366). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Direct Rx, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Label)

Label (Label)
AMOXICILLIN 875mg tablet packaging label showing 20 tablets per container by Direct RX. The yellow and white label states the dosage strength of 875mg, dosage form as film coated tablets, and distribution information including a discard date of 08/16 and the lot number Prod# 366-20. Manufacturer and package location details are partially visible.*
FDA Label Image

Image Description (Structure)

Image Description (Structure)
Chemical structure of amoxicillin labeled with the product name AMOXICILLIN from Direct RX. The structure shows the key molecular components and bonding including the beta-lactam ring and side groups characteristic of amoxicillin.*
FDA Label Image

Image Description (Table01)

Image Description (Table01)
A dosing recommendation table for Amoxicillin for adult and pediatric patients over 3 months of age. It details usual adult doses and usual doses for children by infection type and severity, including doses for ear/nose/throat, skin, genitourinary tract, lower respiratory tract infections, and acute uncomplicated gonorrhea. The table includes notes on pediatric dosing adjustments and contraindications for children under 2 years when combined with probenecid.*
FDA Label Image

Image Description (Table03)

Image Description (Table03)
A data table titled 'Mean Pharmacokinetic Parameters of Amoxicillin (400 mg chewable tablets and 400 mg/5 mL suspension) in Healthy Adults.' It compares the AUC0-∞ and Cmax values for two forms of amoxicillin dosage: 400 mg in 5 mL suspension and 400 mg as one chewable tablet, including standard deviations. Notes specify administration at the start of a light meal and mean values from 24 volunteers with peak concentrations about 1 hour post-dose.*
FDA Label Image

Image Description (Table04)

Image Description (Table04)
A table titled 'Susceptibility Test Interpretive Criteria for Amoxicillin' presenting minimum inhibitory concentration (mcg/mL) and disk diffusion zone diameter (mm) criteria for susceptibility, intermediate, and resistance status across various bacterial species including Enterococcus spp., Staphylococcus spp., Streptococci groups, Enterobacteriaceae, Haemophilus influenzae, and Neisseria gonorrhoeae. The table includes footnotes about testing protocols for Streptococcus pneumoniae and beta lactamase test implications.*
FDA Label Image

Image Description (Table05)

Image Description (Table05)
A data table titled 'Acceptable Quality Control Ranges for Amoxicillin,' listing bacteria species, their ATCC numbers, MIC ranges (mcg/mL), and disc diffusion zone ranges (mm). It includes entries for Escherichia coli, Enterococcus faecalis, Haemophilus influenzae, Staphylococcus aureus, and Streptococcus pneumoniae, with corresponding values for quality control parameters.*
FDA Label Image

Image Description (Table06)

Image Description (Table06)
A data table titled 'H. pylori Eradication Rates When Amoxicillin is Administered as Part of a Triple Therapy Regimen.' It presents eradication rates from two studies comparing evaluable analysis and intent-to-treat analysis, with values given as percentages with 95% confidence intervals and patient numbers. Detailed footnotes explain patient inclusion criteria and analysis methods.*
FDA Label Image

Image Description (Table07)

Image Description (Table07)
A data table titled 'Table 7. H. pylori Eradication Rates When Amoxicillin is Administered as Part of a Dual Therapy Regimen.' The table compares eradication rates between two studies under two analysis types: Evaluable Analysis and Intent-to-Treat Analysis, each with 95% confidence intervals and patient numbers. Footnotes explain criteria for patient inclusion in analyses.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.